GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress
ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC.